SoftOx Solutions AS - Asset Resilience Ratio
SoftOx Solutions AS (SOFTX) has an Asset Resilience Ratio of 17.07% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. For the complete balance sheet picture, see SoftOx Solutions AS (SOFTX) total assets.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how SoftOx Solutions AS's Asset Resilience Ratio has changed over time. Read SoftOx Solutions AS (SOFTX) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down SoftOx Solutions AS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. See SoftOx Solutions AS (SOFTX) liquidity interval to measure how many days the company can operate on defensive assets alone.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr20.06 Million | 17.07% |
| Short-term Investments | Nkr0.00 | 0% |
| Total Liquid Assets | Nkr20.06 Million | 17.07% |
Asset Resilience Insights
- Good Liquidity Position: SoftOx Solutions AS maintains a healthy 17.07% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
SoftOx Solutions AS Industry Peers by Asset Resilience Ratio
Compare SoftOx Solutions AS's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX |
Biotechnology | 0.00% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 10.17% |
|
Absci Corp
NASDAQ:ABSI |
Biotechnology | 59.86% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for SoftOx Solutions AS (2016–2024)
The table below shows the annual Asset Resilience Ratio data for SoftOx Solutions AS.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 8.68% | Nkr10.51 Million ≈ $1.11 Million |
Nkr121.14 Million ≈ $12.75 Million |
+0.81pp |
| 2023-12-31 | 7.87% | Nkr7.65 Million ≈ $805.24K |
Nkr97.24 Million ≈ $10.23 Million |
-1.00pp |
| 2022-12-31 | 8.87% | Nkr6.91 Million ≈ $726.82K |
Nkr77.83 Million ≈ $8.19 Million |
-44.29pp |
| 2021-12-31 | 53.17% | Nkr56.98 Million ≈ $6.00 Million |
Nkr107.18 Million ≈ $11.28 Million |
+13.31pp |
| 2020-12-31 | 39.86% | Nkr34.80 Million ≈ $3.66 Million |
Nkr87.31 Million ≈ $9.19 Million |
-32.54pp |
| 2019-12-31 | 72.40% | Nkr76.00 Million ≈ $8.00 Million |
Nkr104.96 Million ≈ $11.05 Million |
+67.12pp |
| 2018-12-31 | 5.29% | Nkr1.24 Million ≈ $130.12K |
Nkr23.39 Million ≈ $2.46 Million |
-49.80pp |
| 2017-12-31 | 55.09% | Nkr17.10 Million ≈ $1.80 Million |
Nkr31.04 Million ≈ $3.27 Million |
+51.68pp |
| 2016-12-31 | 3.41% | Nkr301.99K ≈ $31.78K |
Nkr8.86 Million ≈ $932.31K |
-- |
About SoftOx Solutions AS
SoftOx Solutions AS, together with its subsidiaries, operates as a clinical-stage pharmaceutical company that anti-infective therapy for airway infections in Norway. The company develops SIS-03, a lead clinical program that is in phase 2a to treatment of chronic airway infections. It also developing pan antimicrobial pharmaceuticals targeting bacteria, viruses, yeast, spores, and fungi. SoftOx So… Read more